Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 24, 2009

Teva-Kowa to Take Majority Stake in Taisho Pharmaceuticals

  • Teva Pharmaceutical Industries and Kowa Company’s Japanese joint venture, Teva-Kowa Pharma, is to acquire a majority stake in Japanese generics specialist Taisho Pharmaceutical Industries. 

    Teva-Kowa plans to purchase at least 66.7% of Taisho’s outstanding shares as part of its move to enhance its position in the Japanese generics market. The company says that buying a majority interest in Taisho will serve as a springboard for operations in the country.

    Taisho’s portfolio includes over 200 generic medicines. The company also operates a finished-dosage manufacturing facility and has R&D capabilities. The firm reported total net sales of ¥129.76 million (about $1.42 million) in the six months ending September 30, 2009. Sales by the company’s self-medication group (OTC drugs, functional foods, and other products) were ¥81.6 million (roughly $0.89 million). Sales by its prescription pharmaceuticals group were ¥48.1 million (approximately $0.52 million).

    Estimates suggest Japan is the second largest pharmaceutical market in the world, valued at some $80 million. According to data by IMS and the Japanese Generics Manufacturing Association, however, in 2006, generics represented just 5.7% of the market or 16.9% in terms of volume. In 2007, the Japanese government announced plans to double generics utilization to 30% by 2012.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »